Nanobiosym attracts major business leader to its global advisory board
This article was originally published in Clinica
Executive Summary
Ratan Tata has joined the global advisory board of Nanobiosym, a medical nanotechnology firm based in Medford, Massachusetts. Mr Tata is chairman of the largest private company in India, the multibillion-dollar multinational conglomerate Tata Group (Mumbai, India). “Mr Tata’s example provides us with a practical roadmap for bringing cutting edge technologies into emerging economies and extending our reach to broad markets at the ‘bottom of the pyramid’,” said Anita Goel, the company’s chairman and CEO. The company’s Gene-RADAR technology is a handheld nanotech platform that can rapidly detect genetic fingerprints from any biological organism, from a drop of blood or saliva. It will facilitate patients’ access to information about their health. Alfred Ford, director of the Ford Motor Company, is also a member of the firm’s global advisory board.
You may also be interested in...
Asia Regulatory Forum Update
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia adopts interim device authorisation regulation
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
Canada takes action to increase more adverse event reporting
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.